Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia

Whitney Perry, Yoav Golan

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP remains a major cause of morbidity, hospital admissions and re-admissions, and mortality. Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against both typical and atypical CAP pathogens. In this review of the medical literature, we summarize the available information, including mounting clinical evidence, about lefamulin and its potential value in CAP.

Original languageEnglish
Pages (from-to)927-939
Number of pages13
JournalFuture Microbiology
Issue number11
StatePublished - 1 Jan 2019
Externally publishedYes


  • community acquired
  • lefamulin
  • pneumonia

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia'. Together they form a unique fingerprint.

Cite this